Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection

Journal of General Virology

Volumn 91, Issue 11, 2010, Pages 2794-2803

  Dreja, Hanna ^a   O'Sullivan, Eithne ^a   Pade, Corinna ^a   Greene, Kelli M ^b   Gao, Hongmei ^b   Aubin, Keith ^a   Hand, James ^a   Isaksen, Are ^a   D'Souza, Carl ^a   Leber, Werner ^c   Montefiori, David ^b   Seaman, Michael S ^d   Anderson, Jane ^c   Orkin, Chloe ^a   McKnight, Áine ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 CLADE B INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 CLADE B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 CLADE C INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 CLADE C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; UNITED KINGDOM; VIRUS NEUTRALIZATION; BLOOD; CLASSIFICATION; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; SERODIAGNOSIS;

ANTIBODIES, NEUTRALIZING; COHORT STUDIES; FEMALE; GENOTYPE; HIV ANTIBODIES; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LONDON; MALE; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NEUTRALIZING ANTIBODY; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE;

EID: 78049370371     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.024224-0     Document Type: Article

References (42)

1. Aasa-Chapman, M., Hayman, A., Newton, P., Cornforth, D., Williams, I., Borrow, P., Balfe, P. & McKnight, A. (2004). Development of the antibody response in acute HIV-1 infection. AIDS 18, 371-381. (Pubitemid 38365863)
2. Arora, P., Kumar, R., Bhattacharya, M., Nagelkerke, N. & Jha, P. (2008). Trends in HIV incidence in India from 2000 to 2007. Lancet 372, 289-290.
3. Barin, F., Brunet, S., Brand, D., Moog, C., Peyre, R., Damond, F., Charneau, P. & Barre-Sinoussi, F. (2004). Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors. J Infect Dis 189, 322-327. (Pubitemid 38147257)
4. Betts, M., Krowka, J., Santamaria, C., Balsamo, K., Gao, F., Mulundu, G., Luo, C., N'Gandu, N., Sheppard, H. & other authors (1997). Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 71, 8908-8911.
5. Braibant, M., Brunet, S., Costagliola, D., Rouzioux, C., Agut, H., Katinger, H., Autran, B. & Barin, F. (2006). Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20, 1923-1930. (Pubitemid 44427609)
6. Brown, B., Wieczorek, L., Sanders-Buell, E., Rosa Borges, A., Robb, M., Birx, D., Michael, N., McCutchan, F. & Polonis, V. (2008). Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375, 529-538.
7. Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S., Abdool-Karim, S. & Montefiori, D. (2002). Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76, 2233-2244. (Pubitemid 34150691)
8. Cao, H., Kanki, P., Sankalé, J., Dieng-Sarr, A., Mazzara, G., Kalams, S., Korber, B., Mboup, S. & Walker, B. (1997). Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol 71, 8615-8623. (Pubitemid 27446443)
9. Cavacini, L., Duval, M., Patil, A., Wood, C., Mayer, K., Ruprecht, R. & Posner, M. (2005). Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: implications for active and passive immunotherapy. J Med Virol 76, 146-152. (Pubitemid 40593997)
10. Corti, D., Langedijk, J., Hinz, A., Seaman, M., Vanzetta, F., Fernandez-Rodriguez, B., Silacci, C., Pinna, D., Jarrossay, D. & other authors (2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805.
11. Doria-Rose, N., Klein, R., Manion, M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C., Migueles, S., Wrammert, J. & other authors (2009). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83, 188-199.
12. Ferrari, G., Humphrey, W., McElrath, M., Excler, J., Duliege, A., Clements, M., Corey, L., Bolognesi, D. & Weinhold, K. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396-1401. (Pubitemid 27087862)
13. Health Protection Agency Centre for Infections, Health Protection Scotland and UCL Institute of Child Health (2010). New HIV diagnoses in the UK by prevention group and estimated world region of infection: 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1252660014023
14. Howard, T. & Rasheed, S. (1996). Genomic structure and nucleotide sequence analysis of a new HIV type 1 subtype A strain from Nigeria. AIDS Res Hum Retroviruses 12, 1413-1425. (Pubitemid 26341534)
15. Koh, W., Forsman, A., Hué, S., van der Velden, G., Yirrell, D., McKnight, A., Weiss, R. & Aasa-Chapman, M. (2010). Novel subtype C HIV-1 envelopes cloned directly from plasma: coreceptor usage and neutralisation phenotypes. J Gen Virol 91, 2374-2380.
16. Kostrikis, L., Cao, Y., Ngai, H., Moore, J. & Ho, D. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 70, 445-458. (Pubitemid 26062950)
17. Li, M., Gao, F., Mascola, J., Stamatatos, L., Polonis, V., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125.
18. Li, B., Decker, J., Johnson, R., Bibollet-Ruche, F., Wei, X., Mulenga, J., Allen, S., Hunter, E., Hahn, B. & other authors (2006a). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80, 5211-5218.
19. Li, M., Salazar-Gonzalez, J., Derdeyn, C., Morris, L., Williamson, C., Robinson, J., Decker, J., Li, Y., Salazar, M. & other authors (2006b). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80, 11776-11790.
20. Louisirirotchanakul, S., Beddows, S., Cheingsong-Popov, R., Shaffer, N., Mastro, T., Auewarakul, P., Likanonsakul, S., Wasi, C. & Weber, J. (1998). Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol 19, 315-320. (Pubitemid 28536039)
21. Lynch, R., Shen, T., Gnanakaran, S. & Derdeyn, C. (2009). Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses 25, 237-248.
22. Mascola, J., Louder, M., Surman, S., Vancott, T., Yu, X., Bradac, J., Porter, K., Nelson, K., Girard, M. & other authors (1996). Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12, 1319-1328. (Pubitemid 26336859)
23. Matthews, T., Langlois, A., Robey, W., Chang, N., Gallo, R., Fischinger, P. & Bolognesi, D. (1986). Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A 83, 9709-9713. (Pubitemid 17223426)
24. McKnight, A., Clapham, P., Goudsmit, J., Cheingsong-Popov, R., Weber, J. & Weiss, R. (1992). Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 6, 799-802.
25. Moore, J., Cao, Y., Ho, D. & Koup, R. (1994). Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 68, 5142-5155. (Pubitemid 24226583)
26. Moore, J., Cao, Y., Leu, J., Qin, L., Korber, B. & Ho, D. (1996). Interand intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 70, 427-444. (Pubitemid 126508812)
27. Nabel, G. (2002). HIV vaccine strategies. Vaccine 20, 1945-1947.
28. Nyambi, P., Nkengasong, J., Lewi, P., Andries, K., Janssens, W., Fransen, K., Heyndrickx, L., Piot, P. & van der Groen, G. (1996). Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 70, 6235-6243. (Pubitemid 26266842)
29. Patel, M., Hoffman, N. & Swanstrom, R. (2008). Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 82, 903-916.
30. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. & other authors (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361, 2209-2220.
31. Richman, D., Wrin, T., Little, S. & Petropoulos, C. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144-4149. (Pubitemid 36418171)
32. Samleerat, T., Braibant, M., Jourdain, G., Moreau, A., Ngo-Giang-Huong, N., Leechanachai, P., Hemvuttiphan, J., Hinjiranandana, T., Changchit, T. & other authors (2008). Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01-AE. J Infect Dis 198, 868-876.
33. Samleerat, T., Thenin, S., Jourdain, G., Ngo-Giang-Huong, N., Moreau, A., Leechanachai, P., Ithisuknanth, J., Pagdi, K., Wannarit, P. & other authors (2009). Maternal neutralizing antibodies against a CRF01-AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387, 388-394.
34. Sather, D., Armann, J., Ching, L., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S. & other authors (2009). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83, 757-769.
35. Seaman, M., Janes, H., Hawkins, N., Grandpre, L., Devoy, C., Giri, A., Coffey, R., Harris, L., Wood, B. & other authors (2010). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84, 1439-1452.
36. Shankarappa, R., Margolick, J., Gange, S., Rodrigo, A., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C., Learn, G. & other authors (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73, 10489-10502.
37. Spira, S., Wainberg, M., Loemba, H., Turner, D. & Brenner, B. (2003). Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51, 229-240. (Pubitemid 36231141)
38. Tomaras, G., Yates, N., Liu, P., Qin, L., Fouda, G., Chavez, L., Decamp, A., Parks, R., Ashley, V. & other authors (2008). Initial Bcell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82, 12449-12463.
39. Weber, J., Fenyö, E., Beddows, S., Kaleebu, P. & Björndal, A. (1996). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 70, 7827-7832.
40. Wei, X., Decker, J., Wang, S., Hui, H., Kappes, J., Wu, X., Salazar-Gonzalez, J., Salazar, M., Kilby, J. & other authors (2003). Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
41. Weiss, R., Clapham, P., Weber, J., Dalgleish, A., Lasky, L. & Berman, P. (1986). Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324, 572-575. (Pubitemid 17185071)
42. Zheng, N. & Daniels, R. (2001). Maintenance of glycoprotein- determined phenotype in an HIV type 1 (pNL43) env gene-cassetting system. AIDS Res Hum Retroviruses 17, 1501-1506. (Pubitemid 33116753)